Do selective radiation dose escalation and tumour hypoxia status impact the loco-regional tumour control after radio-chemotherapy of head & neck tumours? The ESCALOX protocol

Steffi U Pigorsch, Jan J Wilkens, Severin Kampfer, Victoria Kehl, Alexander Hapfelmeier, Christian Schläger, Henning Bier, Markus Schwaiger, Stephanie E Combs, Steffi U Pigorsch, Jan J Wilkens, Severin Kampfer, Victoria Kehl, Alexander Hapfelmeier, Christian Schläger, Henning Bier, Markus Schwaiger, Stephanie E Combs

Abstract

Background: Standard of care primary treatment of carcinoma of locally advanced squamous cell head and neck cancer (LAHNSCC) consists of platinum-based concomitant chemo-irradiation. Despite progress in the treatment of LAHNSCC using modern radiotherapy techniques the outcome remains still poor. Using IMRT with SIB the escalation of total dose to the GTV is possible with the aim to improve clinical outcome. This study tests the hypothesis if radiation dose escalation to the GTV improves 2-year-LRC and -OS after concomitant chemo-irradiation.

Methods: The ESCALOX trial is a prospective randomized phase III study using cisplatin chemo-irradiation and the SIB-IMRT concept in patients with LAHNSCC of the oral cavity, oropharynx or hypopharynx to escalate the total dose to the GTV up to 80.5 Gy. Chemotherapy is planned either in the 1st and 5th week (cisplatin 20 mg/m2/d d 1-5 and d 29-33) or weekly (cisplatin 40 mg/m2/d) during RT. RT is delivered as SIB with total doses of 80.5 Gy/70.0 Gy/56.0 Gy with 2.3 Gy/2.0 Gy and 1.6 Gy in the experimental arm and in the control arm with 70.0 Gy/56.0 Gy with 2.0 Gy and 1.6 Gy. A pre-study with dose escalation up to 77.0 Gy/70.0 Gy/56.0 Gy with 2.2 Gy/2.0 Gy and 1.6 Gy is demanded by the German federal office of radiation protection (BfS). In the translational part of the trial 100 of the randomised patients will be investigated by 18-F-FMiso-PET-CT for the presence and behaviour of tumor hypoxia twice in the week before treatment start.

Discussion: The primary endpoint of the pre-study is acute radiation induced toxicity. Primary endpoint of the main trial is 2-year-LRC. By using the dose escalation up to 80.5 Gy to the GTV of the primary tumor and lymph nodes > 2 cm a LRC benefit of 15% at 2 years should be expected. The ESCALOX trial is supported by Deutsche Forschungsgemeinschaft (DFG); Grant No.: MO-363/4-1.

Trial registration: ClinicalTrials.gov Identifier: NCT 01212354 , EudraCT-No.: 2010-021139-15.

Trial registration: ClinicalTrials.gov NCT01212354.

Keywords: Chemo-irradiation; Dose escalation; Head and neck cancer; Randomized prospective trial.

Figures

Fig. 1
Fig. 1
ESCALOX - Trial scheme

References

    1. (Hrsg.) ZfKiRK-I . Bericht zum Krebsgeschehen in Deutschland 2016. In: Koch-Institut ZfKiR, editor. Bericht zum Krebsgeschehen in Deutschland 2016. Berlin: Robert-Koch-Institut; 2016.
    1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int Jcancer. 2010;127(12):2893–2917. doi: 10.1002/ijc.25516.
    1. Pignon JP, Bourhis J, Domenge C, Designe L. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet. 2000;355(9208):949–955. doi: 10.1016/S0140-6736(00)90011-4.
    1. Pignon JP, le Maitre A, Maillard E, Bourhis J, Group M-NC. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol. 2009;92(1):4–14. doi: 10.1016/j.radonc.2009.04.014.
    1. Blanchard P, Baujat B, Holostenco V, Bourredjem A, Baey C, Bourhis J, Pignon JP, group M-CC Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): a comprehensive analysis by tumour site. Radiother Oncol. 2011;100(1):33–40. doi: 10.1016/j.radonc.2011.05.036.
    1. Lee NY, Le QT. New developments in radiation therapy for head and neck cancer: intensity-modulated radiation therapy and hypoxia targeting. Semin Oncol. 2008;35(3):236–250. doi: 10.1053/j.seminoncol.2008.03.003.
    1. Seung S, Bae J, Solhjem M, Bader S, Gannett D, Hansen EK, Louie J, Underhill K, Cha C. Intensity-modulated radiotherapy for head-and-neck cancer in the community setting. Int J Radiat Oncol Biol Phys. 2008;72(4):1075–1081. doi: 10.1016/j.ijrobp.2008.02.016.
    1. Studer G, Furrer K, Davis BJ, Stoeckli SS, Zwahlen RA, Luetolf UM, Glanzmann C. Postoperative IMRT in head and neck cancer. Radiat Oncol. 2006;1:40. doi: 10.1186/1748-717X-1-40.
    1. Studer G, Huguenin PU, Davis JB, Kunz G, Lutolf UM, Glanzmann C. IMRT using simultaneously integrated boost (SIB) in head and neck cancer patients. Radiat Oncol. 2006;1:7. doi: 10.1186/1748-717X-1-7.
    1. Huang K, Xia P, Chuang C, Weinberg V, Glastonbury CM, Eisele DW, Lee NY, Yom SS, Phillips TL, Quivey JM. Intensity-modulated chemoradiation for treatment of stage III and IV oropharyngeal carcinoma: the University of California-San Francisco experience. Cancer. 2008;113(3):497–507. doi: 10.1002/cncr.23578.
    1. Budach W, Hehr T, Budach V, Belka C, Dietz K. A meta-analysis of hyperfractionated and accelerated radiotherapy and combined chemotherapy and radiotherapy regimens in unresected locally advanced squamous cell carcinoma of the head and neck. BMC Cancer. 2006;6:28. doi: 10.1186/1471-2407-6-28.
    1. Negi P, Kingsley PA, Srivastava H, Sharma SK. Three Weekly Versus Weekly Cisplatin as Radiosensitizer in Head and Neck Cancer: a Decision Dilemma. Asian Pac J Cancer Prev. 2016;17(4):1617–1623. doi: 10.7314/APJCP.2016.17.4.1617.
    1. Nguyen-Tan PF, Zhang Q, Ang KK, Weber RS, Rosenthal DI, Soulieres D, Kim H, Silverman C, Raben A, Galloway TJ, et al. Randomized phase III trial to test accelerated versus standard fractionation in combination with concurrent cisplatin for head and neck carcinomas in the Radiation Therapy Oncology Group 0129 trial: long-term report of efficacy and toxicity. J Clin Oncol Off J Am Soc Clin Oncol. 2014;32(34):3858–3866. doi: 10.1200/JCO.2014.55.3925.
    1. Michiels S, Le Maitre A, Buyse M, Burzykowski T, Maillard E, Bogaerts J, Vermorken JB, Budach W, Pajak TF, Ang KK, et al. Surrogate endpoints for overall survival in locally advanced head and neck cancer: meta-analyses of individual patient data. Lancet Oncol. 2009;10(4):341–350. doi: 10.1016/S1470-2045(09)70023-3.
    1. Bourhis J, Overgaard J, Audry H, Ang KK, Saunders M, Bernier J, Horiot JC, Le Maitre A, Pajak TF, Poulsen MG, et al. Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis. Lancet. 2006;368(9538):843–854. doi: 10.1016/S0140-6736(06)69121-6.
    1. Beitler JJ, Zhang Q, Fu KK, Trotti A, Spencer SA, Jones CU, Garden AS, Shenouda G, Harris J, Ang KK. Final results of local-regional control and late toxicity of RTOG 9003: a randomized trial of altered fractionation radiation for locally advanced head and neck cancer. Int J Radiat Oncol Biol Phys. 2014;89(1):13–20. doi: 10.1016/j.ijrobp.2013.12.027.
    1. Fu KK, Pajak TF, Trotti A, Jones CU, Spencer SA, Phillips TL, Garden AS, Ridge JA, Cooper JS, Ang KK. A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003. Int J Radiat Oncol Biol Phys. 2000;48(1):7–16. doi: 10.1016/S0360-3016(00)00663-5.
    1. Budach V, Stuschke M, Budach W, Baumann M, Geismar D, Grabenbauer G, Lammert I, Jahnke K, Stueben G, Herrmann T, et al. Hyperfractionated accelerated chemoradiation with concurrent fluorouracil-mitomycin is more effective than dose-escalated hyperfractionated accelerated radiation therapy alone in locally advanced head and neck cancer: final results of the radiotherapy cooperative clinical trials group of the German Cancer Society 95–06 Prospective Randomized Trial. J Clin Oncol Off J Am Soc Clin Oncol. 2005;23(6):1125–1135. doi: 10.1200/JCO.2005.07.010.
    1. Budach V, Stromberger C, Poettgen C, Baumann M, Budach W, Grabenbauer G, Marnitz S, Olze H, Wernecke KD, Ghadjar P. Hyperfractionated accelerated radiation therapy (HART) of 70.6 Gy with concurrent 5-FU/Mitomycin C is superior to HART of 77.6 Gy alone in locally advanced head and neck cancer: long-term results of the ARO 95–06 randomized phase III trial. Int J Radiat Oncol Biol Phys. 2015;91(5):916–924. doi: 10.1016/j.ijrobp.2014.12.034.
    1. Okunieff P, Morgan D, Niemierko A, Suit HD. Radiation dose–response of human tumors. Int J Radiat Oncol Biol Phys. 1995;32(4):1227–1237. doi: 10.1016/0360-3016(94)00475-Z.
    1. Fowler JF. Correction to Kasibhatla et al. How much radiation is the chemotherapy worth in advanced head and neck cancer? (Int j radiat oncol biol phys 2007;68:1491–1495) Int J Radiat Oncol Biol Phys. 2008;71(2):326–329. doi: 10.1016/j.ijrobp.2008.01.052.
    1. Nutting CM, Morden JP, Harrington KJ, Urbano TG, Bhide SA, Clark C, Miles EA, Miah AB, Newbold K, Tanay M, et al. Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial. Lancet Oncol. 2011;12(2):127–136. doi: 10.1016/S1470-2045(10)70290-4.
    1. Gupta T, Agarwal J, Jain S, Phurailatpam R, Kannan S, Ghosh-Laskar S, Murthy V, Budrukkar A, Dinshaw K, Prabhash K, et al. Three-dimensional conformal radiotherapy (3D-CRT) versus intensity modulated radiation therapy (IMRT) in squamous cell carcinoma of the head and neck: a randomized controlled trial. Radiot Oncology. 2012;104(3):343–348. doi: 10.1016/j.radonc.2012.07.001.
    1. Ghosh-Laskar S, Yathiraj PH, Dutta D, Rangarajan V, Purandare N, Gupta T, Budrukkar A, Murthy V, Kannan S, Agarwal JP. Prospective randomized controlled trial to compare 3-dimensional conformal radiotherapy to intensity-modulated radiotherapy in head and neck squamous cell carcinoma: Long-term results. Head neck. 2016;38(Suppl 1):E1481–1487. doi: 10.1002/hed.24263.
    1. Guerrero Urbano T, Clark CH, Hansen VN, Adams EJ, A’Hern R, Miles EA, McNair H, Bidmead M, Warrington AP, Dearnaley DP, et al. A phase I study of dose-escalated chemoradiation with accelerated intensity modulated radiotherapy in locally advanced head and neck cancer. Radiot Oncol. 2007;85(1):36–41. doi: 10.1016/j.radonc.2007.07.011.
    1. Schwartz M, Vuong T, Ballivy O, Parker W, Patrocinio H. Accelerated radiotherapy with simultaneous integrated boost fractionation and intensity-modulated radiotherapy for advanced head and neck cancer. Otolaryngol Head Neck Surg. 2007;136(4):549–555. doi: 10.1016/j.otohns.2006.10.044.
    1. de Arruda FF, Puri DR, Zhung J, Narayana A, Wolden S, Hunt M, Stambuk H, Pfister D, Kraus D, Shaha A, et al. Intensity-modulated radiation therapy for the treatment of oropharyngeal carcinoma: the Memorial Sloan-Kettering Cancer Center experience. Int J Radiat Oncol Biol Phys. 2006;64(2):363–373. doi: 10.1016/j.ijrobp.2005.03.006.
    1. Madani I, Duprez F, Boterberg T, Van de Wiele C, Bonte K, Deron P, De Gersem W, Coghe M, De Neve W. Maximum tolerated dose in a phase I trial on adaptive dose painting by numbers for head and neck cancer. Radiot Oncol. 2011;101(3):351–355. doi: 10.1016/j.radonc.2011.06.020.
    1. Duprez F, De Neve W, De Gersem W, Coghe M, Madani I. Adaptive dose painting by numbers for head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2011;80(4):1045–1055. doi: 10.1016/j.ijrobp.2010.03.028.
    1. Lauve A, Morris M, Schmidt-Ullrich R, Wu Q, Mohan R, Abayomi O, Buck D, Holdford D, Dawson K, Dinardo L, et al. Simultaneous integrated boost intensity-modulated radiotherapy for locally advanced head-and-neck squamous cell carcinomas: II--clinical results. Int J Radiat Oncol Biol Phys. 2004;60(2):374–387. doi: 10.1016/j.ijrobp.2004.03.010.
    1. Rasmussen JH, Hakansson K, Vogelius IR, Aznar MC, Fischer BM, Friborg J, Loft A, Kristensen CA, Bentzen SM, Specht L. Phase I trial of 18 F-Fludeoxyglucose based radiation dose painting with concomitant cisplatin in head and neck cancer. Radiot Oncol. 2016;120(1):76–80. doi: 10.1016/j.radonc.2016.03.005.
    1. Dunst J, Stadler P, Becker A, Lautenschlager C, Pelz T, Hansgen G, Molls M, Kuhnt T. Tumor volume and tumor hypoxia in head and neck cancers. The amount of the hypoxic volume is important. Strahlenther Onkol. 2003;179(8):521–526. doi: 10.1007/s00066-003-1066-4.
    1. Dunst J, Kuhnt T, Strauss HG, Krause U, Pelz T, Koelbl H, Haensgen G. Anemia in cervical cancers: impact on survival, patterns of relapse, and association with hypoxia and angiogenesis. Int J Radiat Oncol Biol Phys. 2003;56(3):778–787. doi: 10.1016/S0360-3016(03)00123-8.
    1. Brizel DM, Sibley GS, Prosnitz LR, Scher RL, Dewhirst MW. Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int J Radiat Oncol Biol Phys. 1997;38(2):285–289. doi: 10.1016/S0360-3016(97)00101-6.
    1. Nordsmark M, Bentzen SM, Rudat V, Brizel D, Lartigau E, Stadler P, Becker A, Adam M, Molls M, Dunst J, et al. Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study. Radiot Oncol. 2005;77(1):18–24. doi: 10.1016/j.radonc.2005.06.038.
    1. Stadler P, Feldmann HJ, Creighton C, Kau R, Molls M. Changes in tumor oxygenation during combined treatment with split-course radiotherapy and chemotherapy in patients with head and neck cancer. Radiot Oncol. 1998;48(2):157–164. doi: 10.1016/S0167-8140(98)00032-2.
    1. Grosu AL, Souvatzoglou M, Roper B, Dobritz M, Wiedenmann N, Jacob V, Wester HJ, Reischl G, Machulla HJ, Schwaiger M, et al. Hypoxia imaging with FAZA-PET and theoretical considerations with regard to dose painting for individualization of radiotherapy in patients with head and neck cancer. Int J Radiat Oncol Biol Phys. 2007;69(2):541–551. doi: 10.1016/j.ijrobp.2007.05.079.
    1. Rischin D, Hicks RJ, Fisher R, Binns D, Corry J, Porceddu S, Peters LJ, Trans-Tasman Radiation Oncology Group S Prognostic significance of [18F]-misonidazole positron emission tomography-detected tumor hypoxia in patients with advanced head and neck cancer randomly assigned to chemoradiation with or without tirapazamine: a substudy of Trans-Tasman Radiation Oncology Group Study 98.02. J Clin Oncol Off J Am Soc Clin Oncol. 2006;24(13):2098–2104. doi: 10.1200/JCO.2005.05.2878.
    1. Rasey JS, Koh WJ, Evans ML, Peterson LM, Lewellen TK, Graham MM, Krohn KA. Quantifying regional hypoxia in human tumors with positron emission tomography of [18 F]fluoromisonidazole: a pretherapy study of 37 patients. Int J Radiat Oncol Biol Phys. 1996;36(2):417–428. doi: 10.1016/S0360-3016(96)00325-2.
    1. Rajendran JG, Schwartz DL, O’Sullivan J, Peterson LM, Ng P, Scharnhorst J, Grierson JR, Krohn KA. Tumor hypoxia imaging with [F-18] fluoromisonidazole positron emission tomography in head and neck cancer. Clin Cancer Res. 2006;12(18):5435–5441. doi: 10.1158/1078-0432.CCR-05-1773.
    1. Eschmann SM, Paulsen F, Bedeshem C, Machulla HJ, Hehr T, Bamberg M, Bares R. Hypoxia-imaging with (18)F-Misonidazole and PET: changes of kinetics during radiotherapy of head-and-neck cancer. Radiot Oncol. 2007;83(3):406–410. doi: 10.1016/j.radonc.2007.05.014.
    1. Wang W, Georgi JC, Nehmeh SA, Narayanan M, Paulus T, Bal M, O’Donoghue J, Zanzonico PB, Schmidtlein CR, Lee NY, et al. Evaluation of a compartmental model for estimating tumor hypoxia via FMISO dynamic PET imaging. Phys Med Biol. 2009;54(10):3083–3099. doi: 10.1088/0031-9155/54/10/008.
    1. Lin Z, Mechalakos J, Nehmeh S, Schoder H, Lee N, Humm J, Ling CC. The influence of changes in tumor hypoxia on dose-painting treatment plans based on 18 F-FMISO positron emission tomography. Int J Radiat Oncol Biol Phys. 2008;70(4):1219–1228. doi: 10.1016/j.ijrobp.2007.09.050.
    1. Nehmeh SA, Lee NY, Schroder H, Squire O, Zanzonico PB, Erdi YE, Greco C, Mageras G, Pham HS, Larson SM, et al. Reproducibility of intratumor distribution of (18)F-fluoromisonidazole in head and neck cancer. Int J Radiat Oncol Biol Phys. 2008;70(1):235–242. doi: 10.1016/j.ijrobp.2007.08.036.
    1. Lee N, Nehmeh S, Schoder H, Fury M, Chan K, Ling CC, Humm J. Prospective trial incorporating pre-/mid-treatment [18 F]-misonidazole positron emission tomography for head-and-neck cancer patients undergoing concurrent chemoradiotherapy. Int J Radiat Oncol Biol Phys. 2009;75(1):101–108. doi: 10.1016/j.ijrobp.2008.10.049.
    1. Thorwarth D, Eschmann SM, Paulsen F, Alber M. A model of reoxygenation dynamics of head-and-neck tumors based on serial 18 F-fluoromisonidazole positron emission tomography investigations. Int J Radiat Oncol Biol Phys. 2007;68(2):515–521. doi: 10.1016/j.ijrobp.2006.12.037.
    1. Zips D, Zophel K, Abolmaali N, Perrin R, Abramyuk A, Haase R, Appold S, Steinbach J, Kotzerke J, Baumann M. Exploratory prospective trial of hypoxia-specific PET imaging during radiochemotherapy in patients with locally advanced head-and-neck cancer. Radiot Oncol. 2012;105(1):21–28. doi: 10.1016/j.radonc.2012.08.019.
    1. Bittner MI, Wiedenmann N, Bucher S, Hentschel M, Mix M, Weber WA, Grosu AL. Exploratory geographical analysis of hypoxic subvolumes using 18 F-MISO-PET imaging in patients with head and neck cancer in the course of primary chemoradiotherapy. Radiot Oncol. 2013;108(3):511–516. doi: 10.1016/j.radonc.2013.06.012.
    1. Eisbruch A, Kim HM, Terrell JE, Marsh LH, Dawson LA, Ship JA. Xerostomia and its predictors following parotid-sparing irradiation of head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2001;50(3):695–704. doi: 10.1016/S0360-3016(01)01512-7.
    1. Studer G, Luetolf UM, Glanzmann C. Locoregional failure analysis in head-and-neck cancer patients treated with IMRT. Strahlenther Onkol. 2007;183(8):417–423. doi: 10.1007/s00066-007-1663-8.
    1. Vosmik M, Odrazka K, Dolezel M, Vaculikova M, Kordac P, Zouhar M, Petera J, Jansa J, Zoul Z, Paluska P, et al. IMRT with the use of simultaneous integrated boost in treatment of head and neck cancer: acute toxicity evaluation. Acta Med. 2006;49(3):167–173.
    1. Pacholke HD, Amdur RJ, Louis DA, Yang H, Mendenhall WM. The role of intensity modulated radiation therapy for favorable stage tumor of the nasal cavity or ethmoid sinus. Am J Clin Oncol. 2005;28(5):474–478. doi: 10.1097/.
    1. Pacholke HD, Amdur RJ, Morris CG, Li JG, Dempsey JF, Hinerman RW, Mendenhall WM. Late xerostomia after intensity-modulated radiation therapy versus conventional radiotherapy. Am J Clin Oncol. 2005;28(4):351–358. doi: 10.1097/01.coc.0000158826.88179.75.
    1. Clavel S, Nguyen DH, Fortin B, Despres P, Khaouam N, Donath D, Soulieres D, Guertin L, Nguyen-Tan PF. Simultaneous integrated boost using intensity-modulated radiotherapy compared with conventional radiotherapy in patients treated with concurrent carboplatin and 5-fluorouracil for locally advanced oropharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 2012;82(2):582–589. doi: 10.1016/j.ijrobp.2010.10.061.
    1. Adelstein DJ, Kalish LA, Adams GL, Wagner H, Jr, Oken MM, Remick SC, Mansour EG, Haselow RE. Concurrent radiation therapy and chemotherapy for locally unresectable squamous cell head and neck cancer: an Eastern Cooperative Oncology Group pilot study. J Clin Oncol Off J Am Soc Clin Oncol. 1993;11(11):2136–2142. doi: 10.1200/JCO.1993.11.11.2136.

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren